Mitoxantrone is an FDA-approved anticancer drug that also acts as a general inhibitor of group I intron self-splicing. Here the authors show that Mitoxantrone repartitions RNA conformational ensembles rather than simply binding RNA, stabilizing specific GC-rich structures. This reduces 5′ UTR heterogeneity and increases translation efficiency.
- Chundan Zhang
- Ivana Borovská
- Danny Incarnato
